ReviewInternational journal of nanomedicine2026
Novel Strategies for Precision Diagnosis and Treatment of Prostate Cancer Based on Multifunctional Nanocarrier Systems.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and its current diagnostic and therapeutic methods still face severe challenges in terms of specificity, efficacy, and toxicity. The emergence of nanotechnology provides a powerful platform to overcome these obstacles. Through the design of sophisticated nanocarriers, targeted delivery and controlled release of therapeutic agents, as well as the synergy of multiple treatment modalities, can be achieved, thereby significantly improving efficacy and reducing side effects. Meanwhile, nanotechnology shows great potential in developing highly sensitive diagnostic tools and theranostic platforms, laying the foundation for early detection and precise treatment of PCa. Although challenges such as scalability and safety remain to be addressed before clinical translation, nanotechnology is undoubtedly reshaping the landscape of PCa management and driving the field towards personalized medicine. This review aims to provide a systematic overview of significant advancements in nanotechnology for the diagnosis and treatment of PCa over the past three years. It focuses on innovative research in novel nanocarrier design, targeting strategies, and the construction of integrated diagnostic and therapeutic platforms. Furthermore, current challenges and future directions for clinical translation are discussed, with the aim of offering valuable insights and references for researchers and clinicians in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.